Intrommune Therapeutics Submits Pre-IND Meeting Request to the US FDA for INT301, Its Peanut Allergy Oral Mucosal … – GlobeNewswire (press release)
GlobeNewswire (press release) |
Intrommune Therapeutics Submits Pre-IND Meeting Request to the US FDA for INT301, Its Peanut Allergy Oral Mucosal …
GlobeNewswire (press release) New York, May 15, 2018 (GLOBE NEWSWIRE) –. Intrommune Therapeutics, a NYC-based biopharmaceutical company developing a patient-friendly immunotherapy platform for the treatment of food allergies, submitted its request for a Pre-IND meeting with … |
